2006). sellckchem controls with major medical comorbidities other than PD such as cancer or other similar chronic diseases were excluded. The baseline weight for the controls was the weight on the chart 2 years prior to the most recent clinic visit. Descriptive statistics (means, variance, proportions) were computed

on both cases and controls. All data are reported as mean ± standard error of Inhibitors,research,lifescience,medical the mean. Regression analyses incorporating age, gender, baseline weight, body mass index (BMI), and case or control were conducted to assess the final weight and weight change using SAS PROC GLM (SAS version 9. 1. 3). Chi-square statistics were used to estimate the proportion of patients who gained weight over the time period, with net weight gain and weight loss defined as any increase or decrease in body weight over the study period. Categorical analyses of change in body mass index (BMI) by National Heart Inhibitors,research,lifescience,medical Lung and Blood Institute (NHLBI) criteria (underweight ≤ 18.5, normal weight 18.5–24.9, overweight and obese ≥ 25) were conducted using chi-square statistics (National Heart, Lung, and Blood Institute, 2000). The Unified Parkinson’s Disease Rating Scale (UPDRS) was measured “off” and Inhibitors,research,lifescience,medical “on” medication in DBS patients at specified intervals, but not in PD controls without DBS (Langston et al. 1992). Results

In this study, 43 consecutive patients with moderate-to-advanced PD underwent successful unilateral STN DBS contralateral to their most affected hemibody, and 25 (58%) of these patients underwent staged bilateral STN DBS within 2 years of their first electrode placement. The average age and duration of disease of the DBS patients were 60.6 ± 1.5 and 14.1 ± 0.90 years, respectively, and the average age and duration Inhibitors,research,lifescience,medical of disease Inhibitors,research,lifescience,medical of the PD controls without DBS were 59.7 ± 1.7 and 11.4

± 0.97 years, respectively. Among all of the patients, 73% were male. The average latency between initial and staged electrode placement was 12.5 ± 1.6 http://www.selleckchem.com/products/Axitinib.html months for patients who elected to have staged bilateral STN DBS within the 2-year interval. Weight gain was statistically significant in both the unilateral and staged bilateral STN DBS patients at 2 years postoperatively versus controls who did not undergo DBS (P < 0.001, respectively). Unilateral STN DBS patients gained 3.9 ± 2.0 kg and Carfilzomib staged bilateral STN DBS patients gained 5.6 ± 2.1 kg, while controls lost 0.8 ± 1.1 kg over the 2-year period (mean ± standard error, Fig. 1). Although the mean weight gain following staged bilateral STN DBS was 1.7 kg greater than that in the unilateral DBS patients at 2 years, this difference was not statistically significant (P = 0.885). The staged bilateral STN DBS patients did gain a mean of 1.4 ± 0.8 kg at 1 year after the second staged surgery versus their weight immediately prior to the second electrode placement (Fig.